Stopping NUC therapy in Piranga

Anna Maria Geretti
Senior Global Medical Director
Roche Pharma Research & Early Development
The Piranga Phase 2 Study

A phase 2, randomised, adaptive, open-label, platform trial to evaluate efficacy and safety of multiple combination therapies for the finite treatment of chronic hepatitis B

Current Population

- Virologically suppressed patients on NUC therapy for ≥12 months

Primary Endpoint

- Efficacy: % patients with HBsAg loss at 24 weeks post-end of treatment

Trial started in July 2020
Concept: To study multiple targeted finite therapies in an ongoing manner, with therapies allowed to enter or leave the platform on the basis of a decision algorithm.

EOT = End-of-treatment
Piranga: Criteria for stopping NUCs

Participants will stop NUCs at any time during the follow-up period if samples taken at EoT (week 48) or at any of the follow-up visits show:

1. ALT <1.25 x baseline values, AND
2. HBV DNA <LLOQ or <20 IU/mL, AND
3. Negative HBeAg (if HBeAg positive at baseline), AND
4. HBsAg at EoT <100 IU/mL (or >1 log reduction from baseline, under review)

FDA’s comments (2019) - Benchmarks that must be met for NUC discontinuation in combo arms: at a minimum, ALT <1.25 X ULN, HBV DNA <LLOQ, HBeAg negative. Also open to consider an absolute threshold in HBsAg level at EoT (in addition to a treatment-induced decrease)*

EMA’s comments (2019) – Same approach advised for discontinuation in NUC control arm as per other arms

*noting that HBsAg decline to a certain plateau is currently not sufficiently validated as a surrogate endpoint for predicting HBsAg loss

LLOQ = lower limit of quantification
# Piranga: Secondary efficacy endpoints

<table>
<thead>
<tr>
<th>Current Population</th>
<th>• Virologically suppressed CHB patients on NUC therapy for ≥12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Endpoint</td>
<td>• Efficacy: % patients with HBsAg loss at 24 weeks post-end of treatment</td>
</tr>
</tbody>
</table>
| Secondary EfficacyEndpoints | • % patients with:  
  i) HBsAg loss/seroconversion  
  ii) HBeAg loss/seroconversion (for HBeAg-positive participants)  
  iii) HBV DNA levels <2,000 IU/ml, <200 IU/ml and <LLOQ  
• Change from baseline in quantitative HBsAg, anti-HBs, HBeAg, anti-HBe, HBV DNA, HBcrAg, HBV RNA* |

*Roche Diagnostics investigational assay for use on the cobas® 6800/8800 Systems; LLOQ 10 copies/ml; linearity range 10 to $10^9$ copies/ml on armoured RNA template